MediPoint: Biopsy Devices - Global Analysis and Market Forecasts

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

MediPoint: Biopsy Devices - Global Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_global_analysis_market_forecasts.html

MediPoint: Biopsy Devices - Global Analysis and Market Forecasts

Summary

Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions.

For this market analysis, the biopsy devices market is segmented by cancer indication and by the type of biopsy procedure performed. Beyond providing a general analysis and forecast for each device segment in different global regions from 2010–2019, this report offers a more granular approach by assessing the adoption patterns of the different biopsy procedure types for specific cancer indications in specific geographies. This report and forecast focus on the adoption patterns of surgical biopsies, fine needle aspiration (FNA) devices, core needle biopsy (CNB) devices, and vacuum-assisted biopsy (VAB) devices in the diagnosis of breast, prostate, lung, liver, and thyroid cancers. Additionally, this report and forecast focus on these adoption patterns in the 10 major global markets, which include the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Brazil, China, and India. This segmentation provides better business intelligence, so that more effective actions can be taken.

While the biopsy devices market has matured quite significantly, there are still significant barriers to overcome and opportunities for growth. While the US has seen the rapid adoption of VAB devices in the diagnosis of breast cancer, this market segment will be subjected to immense pricing pressure during the forecast period covered in this report. Changes in the reimbursement rates for image-guided breast biopsy procedures will affect both the average selling prices (ASPs) of these devices and the adoption levels of alternative tissue-extraction devices and procedures, including CNBs and open surgical biopsies. Additionally, the emerging economies will provide opportunities for growth as access to healthcare improves, adoption of FNA decreases, and governments work towards implementing cancer screening programs. This report is intended to elaborate on these market opportunities and barriers to help current and future competitors navigate the market.

Highlights

Key Questions Answered

- At the start of 2014, the reimbursement scheme for imaged-guided breast biopsy procedures performed in the US underwent significant changes in coding structure and cost levels. (Q). How will this affect the adoption of VAB and CNB devices in the country? (Q). To what extent will the ASPs of VAB devices be affected?
- The biopsy devices markets in the developing economies of the Asia-Pacific (APAC) region and Brazil have higher Compound Annual Growth Rates (CAGRs) than any other country included in this report. (Q). Which countries will have the highest CAGRs in the FNA market, the CNB market, and the VAB market?
- The major players in the VAB and CNB markets are drastically different. (Q). What is the global company share in the VAB and CNB markets? (Q). How will their market share shift through 2019?
- New technologies, such as liquid and optical biopsies, are being developed as less invasive techniques to obtain a cancer diagnosis. (Q). What is the likelihood that these technologies could replace the conventional biopsy devices? (Q). Which companies are the furthest along in the development of these technologies?
- The benefits of mass screening programs on prostate cancer mortality are controversial. (Q). What are the results of the major randomized clinical trials assessing a prostate cancer screening program's effectiveness? (Q). How will this impact the institution of a mass prostate cancer screening program in the countries covered in this report?

Reasons to buy

- "What Do Physicians Think?" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision-makers in every organization, allowing them to act on high-quality information.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 13
2 Introduction 15
2.1 Overview 15
2.2 Catalyst 16
2.3 Related Reports 16
3 Industry Overview 17
3.1 Types of Biopsies 17
3.1.1 Surgical Biopsy 17
3.1.2 Fine Needle Aspiration 17
3.1.3 Core Needle Biopsy 18
3.1.4 Vacuum-Assisted Biopsy 19
3.2 Biopsy Procedure Trends 19
3.2.1 Global 19
3.2.2 United States 20
3.2.3 EU 22
3.2.4 South America 29
3.2.5 Asia-Pacific Region 30
3.3 Market Access to Cancer Screening Programs 36
3.3.1 Regulation 36
3.3.2 Biopsy Device Adoption Patterns 39
3.3.3 Reimbursement Trends 43
3.4 Regulatory Issues/Recalls 44
3.5 Mergers & Acquisitions/Key Partnerships 45
3.5.1 Hologic Acquires Suros Surgical Systems 45
3.5.2 C. R. Bard Acquires SenoRx 45
3.5.3 Devicor Medical Products Acquires Breast Care Portfolio from Ethicon Endo-Surgery 46
3.6 Economic Impact of Cancer Screening and Treatment 46
3.7 Additional Indications for Biopsy Devices 47
4 Unmet Needs 48
4.1 Overview 48
4.2 More Efficient Screening Tests for Prostate Cancer 48
4.3 More Efficient Screening Tests for Breast Cancer 49
4.4 More Efficient Screening Guidelines for Thyroid Cancer 49
4.5 Screening Tests That Can Provide Histological Analysis In Situ 50
5 Market Opportunity Analysis 51
5.1 Increase Marketing for Vacuum-Assisted Biopsy Devices in European Countries 51
5.2 Bundling Solutions 52
5.3 Focus Efforts on China's Increasing Adoption of VAB Devices 53
5.4 Market for Prostate Cancer Screening Coverage in Europe 53
6 Market Drivers and Barriers 55
6.1 Market Drivers 55
6.1.1 Inadequate Screening Tests for Particular Cancers 55
6.1.2 Demand for Minimally-Invasive Biopsy Techniques 56
6.1.3 Increased Adherence to Certain Cancer Screening Guidelines 56
6.1.4 Aging Patient Population 57
6.2 Market Barriers 58
6.2.1 Increased Competition from Other Cancer Diagnostic Tests 58
6.2.2 Breast Biopsy Reimbursement Bundling 61
6.2.3 Decreased Adherence to Certain Cancer Screening Guidelines 64
6.2.4 Benefits of Mass Prostate Cancer Screening Being Outweighed by Risks 64
7 Competitive Assessment 66
7.1 Overview 66
7.2 Classification Based on System 66
7.2.1 Vacuum-Assisted Biopsy Devices 66
7.2.2 Core Needle Biopsy Devices 68
7.2.3 Fine Needle Aspiration Devices 69
8 Pipeline Assessment 71
8.1 Overview 71
8.1.1 Optical Biopsy 72
8.1.2 Liquid Biopsy 73
9 Clinical Trial Analysis 74
10 Current and Future Players 76
10.1 Trends in Corporate Strategy 76
10.2 Company Profiles 76
10.2.1 Argon Medical Devices 76
10.2.2 Boston Scientific 79
10.2.3 Cardinal Health 82
10.2.4 CareFusion Corporation 83
10.2.5 Cook Medical 85
10.2.6 C. R. Bard 88
10.2.7 Devicor Medical Products 94
10.2.8 DTR Medical 98
10.2.9 Gallini Medical Devices 99
10.2.10 Hologic 102
10.2.11 INRAD 105
10.2.12 Intact Medical Corporation 107
10.2.13 TSK Laboratory 109
11 Market Outlook 111
11.1 Company Market Share 111
11.1.1 Vacuum-Assisted Biopsy Market Share 111
11.1.2 Core Needle Biopsy/Fine Needle Aspiration Market Share 113
11.2 By Segment 114
11.2.1 Fine Needle Aspiration 114
11.2.2 Core Needle Biopsy 115
11.2.3 Vacuum-Assisted Biopsy 116
11.3 By Geography 117
11.3.1 Global 117
11.3.2 United States 118
11.3.3 France 120
11.3.4 Germany 121
11.3.5 Italy 123
11.3.6 Spain 124
11.3.7 United Kingdom 126
11.3.8 Japan 127
11.3.9 Brazil 129
11.3.10 China 130
11.3.11 India 132
12 Appendix 134
12.1 Bibliography 134
12.2 Abbreviations 142
12.3 Report Methodology 145
12.3.1 Overview 145
12.3.2 Coverage 145
12.3.3 Primary Research 145
12.3.4 Secondary Research 146
12.3.5 Forecasting Methodology 147
12.4 Key Opinion Leaders Included in This Study 147
12.5 About the Authors 148
12.5.1 Joseph A. Gregory, Analyst, Surgical Devices 148
12.5.2 Derek Archila, MBA, Director of Research and Analysis, Medical Devices 148
12.6 Global Head of Healthcare 149
12.6.1 Bonnie Bain, Ph.D., Global Head of Healthcare 149
12.7 About MediPoint 150
12.8 About GlobalData 150
12.9 Disclaimer 150

List of Tables

Table 1: Breast Cancer Incidence Rates, 5EU, 2010-2019 24
Table 2: Biopsy Device Adoption Patterns in Diagnosing Prostate Cancer, Global, 2013 and 2019 40
Table 3: Biopsy Device Adoption Patterns in Diagnosing Breast Cancer, Global, 2013 and 2019 40
Table 4: Biopsy Device Adoption Patterns in Diagnosing Lung Cancer, Global, 2013 and 2019 41
Table 5: Biopsy Device Adoption Patterns in Diagnosing Liver Cancer, Global, 2013 and 2019 42
Table 6: Biopsy Device Adoption Patterns in Diagnosing Thyroid Cancer, Global, 2013 and 2019 43
Table 7: Age Demographics, Age >65 Years, Global, 2013 57
Table 8: Stereotactic Breast Biopsy Ambulatory Surgery Center Billing, 2011 62
Table 9: Stereotactic Breast Biopsy Physician Billing, 2011 62
Table 10: Company Profile - Argon Medical Devices 77
Table 11: Product Portfolio - Argon Medical Devices 78
Table 12: Argon Medical Devices, SWOT Analysis, 2013 78
Table 13: Company Profile - Boston Scientific 79
Table 14: Product Portfolio - Boston Scientific 81
Table 15: Boston Scientific SWOT Analysis, 2013 81
Table 16: Company Profile - Cardinal Health 82
Table 17: Product Portfolio - Cardinal Health 83
Table 18: Cardinal Health SWOT Analysis, 2013 83
Table 19: Company Profile - CareFusion Corporation 84
Table 20: Product Portfolio - CareFusion 85
Table 21: CareFusion, SWOT Analysis, 2013 85
Table 22: Company Profile - Cook Medical 86
Table 23: Product Portfolio - Cook Medical 87
Table 24: Cook Medical, SWOT Analysis, 2013 88
Table 25: Company Profile - C. R. Bard 89
Table 26: Product Portfolio - C. R. Bard 89
Table 27: C.R. Bard, SWOT Analysis, 2013 93
Table 28: Company Profile - Devicor Medical Products 94
Table 29: Product Portfolio - Devicor Medical Products 97
Table 30: Devicor Medical Products SWOT Analysis, 2013 97
Table 31: Company Profile - DTR Medical 98
Table 32: Product Portfolio - DTR Medical 98
Table 33: DTR Medical SWOT Analysis, 2013 99
Table 34: Company Profile - Gallini Medical Devices 100
Table 35: Product Portfolio - Gallini Medical Devices 101
Table 36: Gallini Medical Devices SWOT Analysis, 2013 101
Table 37: Company Profile - Hologic 102
Table 38: Product Portfolio - Hologic 104
Table 39: Hologic SWOT Analysis, 2013 104
Table 40: Company Profile - INRAD 105
Table 41: Product Portfolio - INRAD 106
Table 42: INRAD SWOT Analysis, 2013 106
Table 43: Company Profile - Intact Medical Corporation 107
Table 44: Product Portfolio - Intact Medical Corporation 108
Table 45: Intact Medical Corporation SWOT Analysis, 2013 108
Table 46: Company Profile - TSK Laboratory 109
Table 47: Product Portfolio - TSK Laboratory 110
Table 48: TSK Laboratory SWOT Analysis, 2013 110
Table 49: VAB, Global Market Share, 2013 112
Table 50: CNB/FNA, Global Market Share, 2013 113
Table 51: Global FNA Device Sales ($m) Forecast, 2010-2019 114
Table 52: Global CNB Device Sales ($m) Forecast, 2010-2019 115
Table 53: Global VAB Device Sales ($m) Forecast, 2010-2019 116
Table 54: Global Biopsy Devices Sales ($m) Forecast, 2010-2019 117
Table 55: United States Biopsy Devices Sales ($m) Forecast, 2010-2019 119
Table 56: France Biopsy Devices Sales ($m) Forecast, 2010-2019 120
Table 57: Germany Biopsy Devices Sales ($m) Forecast, 2010-2019 122
Table 58: Italy Biopsy Devices Sales ($m) Forecast, 2010-2019 123
Table 59: Spain Biopsy Devices Sales ($m) Forecast, 2010-2019 125
Table 60: United Kingdom Biopsy Devices Sales ($m) Forecast, 2010-2019 126
Table 61: Japan Biopsy Devices Sales ($m) Forecast, 2010-2019 128
Table 62: Brazil Biopsy Devices Sales ($m) Forecast, 2010-2019 129
Table 63: China Biopsy Devices Sales ($m) Forecast, 2010-2019 131
Table 64: India Biopsy Devices Sales ($m) Forecast, 2010-2019 132

List of Figures

Figure 1: Biopsy Procedure Volumes: All Indications, United States, 2010-2019 21
Figure 2: Biopsy Procedure Volumes: Prostate, 5EU, 2010-2019 23
Figure 3: Biopsy Procedure Volumes: Breast, 5EU, 2010-2019 24
Figure 4: Biopsy Procedure Volumes: Lung, 5EU, 2010-2019 26
Figure 5: Biopsy Procedure Volumes: Liver, 5EU, 2010-2019 27
Figure 6: Biopsy Procedure Volumes: Thyroid, 5EU, 2010-2019 28
Figure 7: Biopsy Procedure Volumes: All Cancer Indications, Brazil, 2010-2019 30
Figure 8: Biopsy Procedure Volumes: Prostate, APAC Region, 2010-2019 31
Figure 9: Biopsy Procedure Volumes: Breast, APAC Region, 2010-2019 32
Figure 10: Biopsy Procedure Volumes: Lung, APAC Region, 2010-2019 33
Figure 11: Biopsy Procedure Volumes: Liver, APAC Region, 2010-2019 34
Figure 12: Biopsy Procedure Volumes: Thyroid, APAC Region, 2010-2019 35
Figure 13: EnCor Breast Biopsy System 90
Figure 14: EnCor Enspire Breast Biopsy System 91
Figure 15: EnCor Ultra Breast Biopsy System 91
Figure 16: Finesse Ultra Breast Biopsy System 92
Figure 17: Vacora Breast Biopsy System 93
Figure 18: Original Mammotome System 95
Figure 19: Mammotome Elite 96
Figure 20: Mammotome Revolve 97
Figure 21: VAB, Global Market Share, 2013 112
Figure 22: CNB/FNA, Global Market Share, 2013 113
Figure 23: Global FNA Device Sales ($m) Forecast, 2010-2019 114
Figure 24: Global CNB Device Sales ($m) Forecast, 2010-2019 115
Figure 25: Global VAB Device Sales ($m) Forecast, 2010-2019 116
Figure 26: Global Biopsy Devices Sales ($) Forecast, 2010-2019 118
Figure 27: United States Biopsy Devices Sales ($) Forecast, 2010-2019 119
Figure 28: France Biopsy Devices Sales ($) Forecast, 2010-2019 121
Figure 29: Germany Biopsy Devices Sales ($) Forecast, 2010-2019 122
Figure 30: Italy Biopsy Devices Sales ($) Forecast, 2010-2019 124
Figure 31: Spain Biopsy Devices Sales ($) Forecast, 2010-2019 125
Figure 32: United Kingdom Biopsy Devices Sales ($) Forecast, 2010-2019 127
Figure 33: Japan Biopsy Devices Sales ($) Forecast, 2010-2019 128
Figure 34: Brazil Biopsy Devices Sales ($) Forecast, 2010-2019 130
Figure 35: China Biopsy Devices Sales ($) Forecast, 2010-2019 131
Figure 36: India Biopsy Devices Sales ($) Forecast, 2010-2019 133

Companies Mentioned

Argon Medical Devices
Boston Scientific
Cardinal Health
CareFusion Corporation
Cook Medical
C. R. Bard
Devicor Medical Products
DTR Medical
Gallini Medical Devices
Hologic
INRAD
Intact Medical Corporation
TSK Laboratory

Read the full report:
MediPoint: Biopsy Devices - Global Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_global_analysis_market_forecasts.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer